SOAT1 and leukemia: The immune-suppressive nature of the TME, influenced by JAK-STAT signaling, may also limit the efficacy of immunotherapies, including chimeric antigen receptor T-cell (CAR-T) cell therapy and immune checkpoint inhibitors, which rely on the activation of T-cells to kill leukemia cells[34].